For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
![Trends](https://imgix-prod.sgs.com/-/media/sgscorp/images/old-do-not-reuse/white-paper-thumbnails/trends-344px.cdn.en.1.jpg?fit=clip&auto=format&w=1504)